Genmab — April 2018
-
Efter en Major incident på hardware, så ville jeg ikke stole særligt meget på den oplyste kursudvikling resten af dagen i dag.
-
Herudover må forventes et lille kursdyk i dag pga. kortsigtet gevinsthjemtagning.
-
I morgen er atter en god (GEN)dag, tror jeg

-
Fred være med det.

-
the small Japanese Dara-D-Vd study was completed https://clinicaltrials.gov/ct2/history/NCT02497378?A=17&B=18&C=merged
-
New study: Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma https://clinicaltrials.gov/ct2/show/NCT03500445?term=NCT03500445&rank=1
-
1/3 af gårsdagens stigning er forduftet pt. De Anonyme er i salgshumør.
-
1205 Så skal der købes imorgen
-
Spørgsmålet er hvornår godkendelsen kommer?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind